Product Benefits

• Dual-Action Control: Combines two powerful antidiabetic agents—a DPP-4 inhibitor and a biguanide—to target blood sugar through multiple biological pathways.

• Improved Insulin Response: Linagliptin increases the release of insulin from the pancreas in a glucose-dependent manner, helping the body process sugar more effectively after meals.

• Reduced Liver Glucose Production: Metformin helps lower basal blood sugar by decreasing the amount of glucose produced and released by the liver.

• Enhanced Sensitivity: Significantly improves the body's natural sensitivity to insulin, allowing peripheral tissues to utilize glucose more efficiently.

• Weight Neutrality: Unlike some other diabetes medications, the combination in Linera M is generally weight-neutral and carries a lower risk of causing significant weight gain.

• Low Hypoglycemia Risk: When used alone, it has a lower risk of causing dangerously low blood sugar compared to sulfonylureas or insulin.

• Comprehensive Complication Defense: By maintaining stable blood sugar levels, it helps reduce the long-term risk of kidney damage, nerve problems, and vision loss.

• Gastrointestinal Tolerability: Formulated to be taken with meals to minimize common stomach-related side effects often associated with high-dose metformin.